For women with epilepsy who wish to start a family, the decision of whether and how to continue anti-seizure medication during pregnancy can be fraught with anxiety. Some of these medications carry an increased risk of adverse pregnancy outcomes, including stillbirths and birth defects. Still, a decades-long Australian initiative, coupled with emerging genetic research, is offering new hope for safer pregnancies and more informed treatment decisions.
A nationwide register, the Australian Pregnancy Register, has been instrumental in dramatically reducing the incidence of these adverse outcomes. Researchers at Monash University have demonstrated the significant benefits of this proactive approach, showing a decrease in stillbirths and birth defects among women with epilepsy who participate in the register. This comes as scientists also explore the potential for a genetic test to further personalize medication choices, minimizing risks for both mother and child.
The Impact of the Australian Pregnancy Register
The Australian Pregnancy Register, established over two decades ago, is one of only a few of its kind globally. It functions as a voluntary, nationwide system collecting data from pregnant women with epilepsy, or those who have recently given birth. This data is crucial for determining which anti-seizure drugs are safest during pregnancy while ensuring expectant mothers continue to receive effective seizure control. Approximately 150,000 people in Australia live with epilepsy according to the Epilepsy Association, making this research particularly impactful.
A recent study led by Associate Professor Zanfina Ademi at Monash University analyzed the economic and health benefits of the register. The findings, published in the peer-reviewed journal Neurology, revealed a substantial positive impact. Researchers estimated that the information gathered through the register led to a decrease of 1,147 stillbirths over a 20-year period, extending to 2019. Approximately 5,500 fewer babies were born with defects, and nearly 2,700 fewer miscarriages occurred as reported by the Epilepsy Association.
Unraveling the Genetic Link
Alongside the success of the pregnancy register, researchers are making strides in understanding the underlying genetic factors that contribute to birth defects in babies born to mothers taking anti-epileptic drugs (AEDs). A study led by Associate Professor Piero Perucca from Monash University’s Department of Neuroscience investigated whether AEDs taken during pregnancy could increase de novo variants – genetic changes appearing for the first time in a family – which were previously thought to be linked to these birth defects. CURE Epilepsy reports that the study, published in Annals of Neurology, found that AEDs do not increase the number of these variants, regardless of whether the baby has birth defects.
The study examined the genomes of 67 children and their parents, including those exposed to AEDs during pregnancy and those who were not. This research suggests that the connection between AEDs and birth defects may be more complex than previously understood, opening avenues for further investigation into other potential contributing factors.
Looking Ahead: Personalized Medicine and Genetic Testing
The combined efforts of the Australian Pregnancy Register and genetic research are paving the way for a future of more personalized medicine in epilepsy care. Monash University scientists are now working towards developing a genetic test that could help identify mothers who are at higher risk of having a child with birth defects while taking certain anti-seizure medications. Monash University News highlights that this test could allow for more informed decisions about medication choices, potentially minimizing risks and maximizing the chances of a healthy pregnancy.
This research represents a significant step forward in empowering women with epilepsy to make informed choices about their reproductive health. The ongoing function of the Australian Pregnancy Register and the development of genetic testing promise a future where women can safely take life-saving medication without fear of adverse outcomes for their children.
The continued collection of data through the Australian Pregnancy Register and further research into the genetic factors involved will be crucial in refining these approaches and improving outcomes for mothers and babies. Share your thoughts and experiences in the comments below.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
